Cannabis, cannabinoids and reproduction

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 70, Issue 2, 2004, Pages 189-197

  Park, Boram ^a   McPartland, John M ^b   Glass, Michelle ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNITEC INSTITUTE OF TECHNOLOGY   (New Zealand)

Author keywords

Cannabinoid; Cannabis; Gestation; Pregnancy; Reproduction

Indexed keywords

CANNABINOID; CANNABIS; LUTEINIZING HORMONE; TETRAHYDROCANNABINOL;

DEVELOPED COUNTRY; FERTILITY; HUMAN; LIFESTYLE; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; REPRODUCTION; REVIEW;

CANNABIS;

EID: 0942279578     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2003.04.007     Document Type: Article

References (128)

1. S. Black, S. Casswell, 'Drugs in New Zealand: a survey, 1990, Alcohol and Public Health Research Unit, Auckland, 1991.
2. Y. Gaoni, R. Mechoulamm, Isolation, structure and partial synthesis of an active constituent of hashish, J. Am. Chem. Soc. 86 (1964) 1646-1647.
3. L.A. Matsuda, S.J. Lolait, M.J. Brownstein, A.C. Young, T.I. Bonner, Structure of a cannabinoid receptor and functional expression of the cloned cDNA, Nature 346 (1990) 561-564.
4. S. Munro, K.L. Thomas, M. Abu-Shaar, Molecular characterization of a peripheral receptor for cannabinoids, Nature 365 (1993) 61-65.
5. S.D. McAllister, M. Glass, CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids, Prostagl. Leukot. Essent. Fatty Acids 66 (2002) 161-171.
6. M. Herkenham, A.B. Lynn, M.D. Little, et al., Cannabinoid receptor localization in brain, Proc. Natl. Acad. Sci. USA 87 (1990) 1932-1936.
7. M. Glass, M. Dragunow, R.L. Faull, Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain, Neuroscience 77 (1997) 299-318.
8. J. McPartland, Marijuana and medicine: the endocrine effects of Cannabis, Altern. Ther. Women's Health 1 (1999) 41-44.
9. J.M. McPartland, P.L. Pruitt, Side effects of pharmaceuticals not elicited by comparable herbal medicines: the case of tetrahydrocannabinol and marijuana, Altern. Ther. Health Med. 5 (1999) 57-62.
10. W.A. Devane, L. Hanus, A. Breuer, et al., Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science 258 (1992) 1946-1949.
11. R. Mechoulam, S. Ben-Shabat, L. Hanus, et al., Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors, Biochem. Pharmacol. 50 (1995) 83-90.
12. L. Hanus, S. Abu-Lafi, E. Fride, et al., 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor, Proc. Natl. Acad. Sci. USA 98 (2001) 3662-3665.
13. A.C. Porter, J.M. Sauer, M.D. Knierman, et al., Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor, J. Pharmacol. Exp. Ther. 301 (2002) 1020-1024.
14. E. Fride, Endocannabinoids in the central nervous system - an overview, Prostagl. Leukot. Essent. Fatty Acids 66 (2002) 221-233.
15. E.D. Hogestatt, P.M. Zygmunt, Cardiovascular pharmacology of anandamide, Prostagl. Leukot. Essent. Fatty Acids 66 (2002) 343-351.
16. J.M. Walker, S.M. Huang, Endocannabinoids in pain modulation, Prostagl. Leukot. Essent. Fatty Acids 66 (2002) 235-242.
17. D. Parolaro, P. Massi, T. Rubino, E. Monti, Endocannabinoids in the immune system and cancer, Prostagl. Leukot. Essent. Fatty Acids 66 (2002) 319-332.
18. K.R. Kozak, L.J. Marnett, Oxidative metabolism of endocannabinoids, Prostagl. Leukot. Essent. Fatty Acids 66 (2002) 211-220.
19. T. Sugiura, Y. Kobayashi, S. Oka, K. Waku, Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance, Prostagl. Leukot. Essent. Fatty Acids 66 (2002) 173-192.
20. V. Di Marzo, L. De Petrocellis, T. Bisogno, S. Maurelli, The endogenous cannabimimetic eicosanoid, anandamide, induces arachidonate release in J774 mouse macrophages, Adv. Exp. Med. Biol. 407 (1997) 341-346.
21. V. Di Marzo, A. Fontana, H. Cadas, et al., Formation and inactivation of endogenous cannabinoid anandamide in central neurons, Nature 372 (1994) 686-691.
22. V. Di Marzo, Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators, Life Sci. 65 (1999) 645-655.
23. M. Beltramo, N. Stella, A. Calignano, S.Y. Lin, A. Makriyannis, D. Piomelli, Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277 (1997) 1094-1097.
24. M. Beltramo, D. Piomelli, Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol, Neuroreport 11 (2000) 1231-1235.
25. B.F. Cravatt, D.K. Giang, S.P. Mayfield, D.L. Boger, R.A. Lerner, N.B. Gilula, Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides, Nature 384 (1996) 83-87.
26. K.R. Kozak, S.W. Rowlinson, L.J. Marnett, Oxygenation of the endocannabinoid, 2-arachidonylglycerol to glyceryl prostaglandins by cyclooxygenase-2, J. Biol. Chem. 275 (2000) 33744-33749.
27. M. Yu, D. Ives, C.S. Ramesha, Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2, J. Biol. Chem. 272 (1997) 21181-21186.
28. W.S. Edgemond, C.J. Hillard, J.R. Falck, C.S. Kearn, W.B. Campbell, Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation, Mol. Pharmacol. 54 (1998) 180-188.
29. L.M. Bornheim, E.T. Everhart, J. Li, M.A. Correia, Characterization of cannabidiol-mediated cytochrome P450 inactivation, Biochem. Pharmacol. 45 (1993) 1323-1331.
30. L.M. Bornheim, K.Y. Kim, B. Chen, M.A. Correia, Microsomal cytochrome P450-mediated liver and brain anandamide metabolism, Biochem. Pharmacol. 50 (1995) 677-686.
31. S.P. Kenney, R. Kekuda, P.D. Prasad, F.H. Leibach, L.D. Devoe, V. Ganapathy, Cannabinoid receptors and their role in the regulation of the serotonin transporter in human placenta, Am. J. Obstet. Gynecol. 181 (1999) 491-497.
32. P.A. Fried, B. Watkinson, A. Grant, R.M. Knights, Changing patterns of soft drug use prior to and during pregnancy: a prospective study, Drug Alcohol Depend. 6 (1980) 323-343.
33. R.A. Sherwood, J. Keating, V. Kavvadia, A. Greenough, T.J. Peters, Substance misuse in early pregnancy and relationship to fetal outcome, Eur. J. Pediatr. 158 (1999) 488-492.
34. B. Zuckerman, D.A. Frank, R. Hingson, et al., Effects of maternal marijuana and cocaine use on fetal growth, N. Engl. J. Med. 320 (1989) 762-768.
35. P.A. Fried, B. Watkinson, A. Willan, Marijuana use during pregnancy and decreased length of gestation, Am. J. Obstet. Gynecol. 150 (1984) 23-27.
36. G.T. Gibson, P.A. Baghurst, D.P. Colley, Maternal alcohol, tobacco and cannabis consumption and the outcome of pregnancy, Aust. NZ J. Obstet. Gynaecol. 23 (1983) 15-19.
37. P.A. Fried, M. Buckingham, P. Von Kulmiz, Marijuana use during pregnancy and perinatal risk factors, Am. J. Obstet. Gynecol. 146 (1983) 992-994.
38. S. Greenland, G.A. Richwald, G.D. Honda, The effects of marijuana use during pregnancy. II. A study in a low-risk home-delivery population, Drug Alcohol Depend. 11 (1983) 359-366.
39. S. Greenland, K.J. Staisch, N. Brown, S.J. Gross, The effects of marijuana use during pregnancy. I. A preliminary epidemiologic study, Am. J. Obstet. Gynecol. 143 (1982) 408-413.
40. A.T. Charlebois, P.A. Fried, Interactive effects of nutrition and cannabis upon rat perinatal development, Dev. Psychobiol. 13 (1980) 591-605.
41. W.F. Geber, L.C. Schramm, Effect of marihuana extract on fetal hamsters and rabbits, Toxicol. Appl. Pharmacol. 14 (1969) 276-282.
42. W.F. Geber, L.C. Schramm, Teratogenicity of marihuana extract as influenced by plant origin and seasonal variation, Arch. Int. Pharmacodyn. Ther. 177 (1969) 224-230.
43. T.V. Persaud, A.C. Ellington, The effects of cannabis sativa L. (Ganja) on developing rat embryos - preliminary observations, West Indian Med. J. 17 (1968) 232-234.
44. R.N. Phillips, D.J. Brown, R.B. Forney, Enhancement of depressant properties of alcohol or barbiturate in combination with aqueous suspended delta 9-tetrahydrocannabinol in rats, J. Forensic Sci. 16 (1971) 152-161.
45. R.N. Phillips, R.F. Turk, R.B. Forney, Acute toxicity of delta-9-tetrahydrocannabinol in rats and mice, Proc. Soc. Exp. Biol. Med. 136 (1971) 260-263.
46. M. Fleishman, Letter: reserpine, ECT, and depression, Am. J. Psychiatry 132 (1975) 1088.
47. R.D. Harbison, B. Mantilla-Plata, D.J. Lubin, Alteration of delta 9-tetrahydrocannabinol-induced teratogenicity by stimulation and inhibition of its metabolism, J. Pharmacol. Exp. Ther. 202 (1977) 455-465.
48. R.D. Harbison, B. Mantilla-Plata, Prenatal toxicity, maternal distribution and placental transfer of tetrahydrocannabinol, J. Pharmacol. Exp. Ther. 180 (1972) 446-453.
49. H. Rosenkrantz, Effects of cannabis on fetal development of rodents, Adv. Biosci. 22-23 (1978) 479-499.
50. R.H. Asch, C.G. Smith, Effects of delta 9THC, the principal psychoactive component of marijuana, during pregnancy in the rhesus monkey, J. Reprod. Med. 31 (1986) 1071-1081.
51. E.N. Sassenrath, L.F. Chapman, G.P. Goo, Reproduction in rhesus monkeys chronically exposed to delta-9-tetrahydrocannabinol, Adv. Biosci. 22-23 (1978) 501-512.
52. S. Dalterio, A. Bartke, Perinatal exposure to cannabinoids alters male reproductive function in mice, Science 205 (1979) 1420-1422.
53. T.F. Murphy, Sperm harvesting and post-mortem fatherhood, Bioethics 9 (1995) 380-398.
54. J.H. Mendelson, N.K. Mello, Reinforcing properties of oral delta 9-tetrahydrocannabinol, smoked marijuana, and nabilone: influence of previous marijuana use, Psychopharmacology (Berl) 83 (1984) 351-356.
55. M.F. Ruh, J.A. Taylor, A.C. Howlett, W.V. Welshons, Failure of cannabinoid compounds to stimulate estrogen receptors, Biochem. Pharmacol. 53 (1997) 35-41.
56. M.A. Sauer, S.M. Rifka, R.L. Hawks, G.B. Cutler Jr., D.L. Loriaux, Marijuana: interaction with the estrogen receptor, J. Pharmacol. Exp. Ther. 224 (1983) 404-407.
57. J.H. Mendelson, N.K. Mello, J. Ellingboe, A.S. Skupny, B.W. Lex, M. Griffin, Marihuana smoking suppresses luteinizing hormone in women, J. Pharmacol. Exp. Ther. 237 (1986) 862-866.
58. J.H. Mendelson, P. Cristofaro, J. Ellingboe, R. Benedikt, N.K. Mello, Acute effects of marihuana on luteinizing hormone in menopausal women, Pharmacol. Biochem. Behav. 23 (1985) 765-768.
59. J.H. Mendelson, N.K. Mello, Effects of marijuana on neuroendocrine hormones in human males and females, NIDA Res. Monogr. 44 (1984) 97-114.
60. J. Bauman, Marijuana and the female reproductive system, in: Health Consequence of Marijuana Use, US Government printing office, Washington, DC, 1980, pp. 85-97.
61. G.D. Braunstein, R.H. Asch, Predictive value analysis of measurements of human chorionic gonadotropin, pregnancy specific beta 1-glycoprotein, placental lactogen, and cystine aminopeptidase for the diagnosis of ectopic pregnancy, Fertil. Steril. 39 (1983) 62-67.
62. R.C. Kolodny, W.H. Masters, R.M. Kolodner, G. Toro, Depression of plasma testosterone levels after chronic intensive marihuana use, N. Engl. J. Med. 290 (1974) 872-874.
63. R. Kolodny, P. Lessin, G. Toro, W.H. Masters, S. Cohen, Depression of plasma testosterone with acute marijuana administration, in: M.C. Braude, S. Szara (Eds.), The Pharmacology of Marijuana, Raven Press, New York, 1976, pp. 217-225.
64. E.J. Cone, R.E. Johnson, J.D. Moore, J.D. Roache, Acute effects of smoking marijuana on hormones, subjective effects and performance in male human subjects, Pharmacol. Biochem. Behav. 24 (1986) 1749-1754.
65. J.H. Mendelson, J. Kuehnle, J. Ellingboe, T.F. Babor, Plasma testosterone levels before, during and after chronic marihuana smoking, N. Engl. J. Med. 291 (1974) 1051-1055.
66. P. Cushman Jr., Plasma testosterone levels in healthy male marijuana smokers, Am. J. Drug Alcohol Abuse 2 (1975) 269-275.
67. W.C. Hembree III, G.G. Nahas, P. Zeidenberg, H.F. Huang, Changes in human spermatozoa associated with high dose marihuana smoking, Adv. Biosci. 22-23 (1978) 429-439.
68. B.T. Ho, G.E. Fritchie, P.M. Kralik, L.F. Englert, W.M. McIsaac, J. Idanpaan-Heikkila, Distribution of tritiated-1 delta 9tetrahydrocannabinol in rat tissues after inhalation, J. Pharm. Pharmacol. 22 (1970) 538-539.
69. R.I. Freudenthal, J. Martin, M.E. Wall, Distribution of delta 9-tetrahydrocannabinol in the mouse, Br. J. Pharmacol. 44 (1972) 244-249.
70. L.L. Murphy, B.A. Adrian, M. Kohli, Inhibition of luteinizing hormone secretion by delta9-tetrahydrocannabinol in the ovariectomized rat: effect of pretreatment with neurotransmitter or neuropeptide receptor antagonists, Steroids 64 (1999) 664-671.
71. I. Nir, D. Ayalon, A. Tsafriri, T. Cordova, H.R. Lindner, Letter: suppression of the cyclic surge of luteinizing hormone secretion and of ovulation in the rat by delta 1-tetrahydrocannabinol, Nature 243 (1973) 470-471.
72. L. Tyrey, Delta-9-tetrahydrocannabinol suppression of episodic luteinizing hormone secretion in the ovariectomized rat, Endocrinology 102 (1978) 1808-1814.
73. C.G. Smith, M.T. Smith, N.F. Besch, R.G. Smith, R.H. Asch, Effect of delta 9-tetrahydrocannabinol (THC) on female reproductive function, Adv. Biosci. 22-23 (1978) 449-467.
74. R.G. Almirez, C.G. Smith, R.H. Asch, The effects of marijuana extract and delta 9-tetrahydrocannabinol on luteal function in the rhesus monkey, Fertil. Steril. 39 (1983) 212-217.
75. R.H. Asch, C.G. Smith, T.M. Siler-Khodr, C.J. Pauerstein, Effects of delta 9-tetrahydrocannabinol during the follicular phase of the rhesus monkey (Macaca mulatta), J. Clin. Endocrinol. Metab. 52 (1981) 50-55.
76. C.G. Smith, N.F. Besch, R.G. Smith, P.K. Besch, Effect of tetrahydrocannabinol on the hypothalamic-pituitary axis in the ovariectomized rhesus monkey, Fertil. Steril. 31 (1979) 335-339.
77. T. Wenger, V. Rettori, G.D. Snyder, S. Dalterio, S.M. McCann, Effects of delta-9-tetrahydrocannabinol on the hypothalamicpituitary control of luteinizing hormone and follicle-stimulating hormone secretion in adult male rats, Neuroendocrinology 46 (1987) 488-493.
78. V. Rettori, M.C. Aguila, M.F. Gimeno, A.M. Franchi, S.M. McCann, In vitro effect of delta 9-tetrahydrocannabinol to stimulate somatostatin release and block that of luteinizing hormone-releasing hormone by suppression of the release of prostaglandin E2, Proc. Natl. Acad. Sci. USA 87 (1990) 10063-10066.
79. T.F. Murphy, Reproductive controls and sexual destiny, Bioethics 4 (1990) 121-142.
80. A.L. Jackson, L.L. Murphy, Role of the hypothalamic-pituitary-adrenal axis in the suppression of luteinizing hormone release by delta-9- tetrahydrocannabinol, Neuroendocrinology 65 (1997) 446-452.
81. R.H. Asch, C.G. Smith, T.M. Siler-Khodr, C.J. Pauerstein, Acute decreases in serum prolactin concentrations caused by delta 9- tetrahydrocannabinol in nonhuman primates, Fertil. Steril. 32 (1979) 571-575.
82. C.L. Hughes Jr., J.W. Everett, L. Tyrey, Delta 9-tetrahydrocannabinol suppression of prolactin secretion in the rat: lack of direct pituitary effect, Endocrinology 109 (1981) 876-880.
83. D. Ayalon, I. Nir, T. Cordova, et al., Acute effect of delta1-tetrahydrocannabinol on the hypothalamo-pituitary-ovarian axis in the rat, Neuroendocrinology 23 (1977) 31-42.
84. L. Tyrey, C.L. Hughes, Inhibition of sucking-induced prolactin secretion by delta-9-tetrahydrocannabinol, in: S.D.W. Agurell, R.E. Wilette (Eds.), The Cannabinoids: Chemical, Pharmacologic and Therapeutic Aspects, Academic Press. San Diego, 1984.
85. F. Rodriguez De Fonseca, J.J. Fernandez-Ruiz, L.L. Murphy, et al., Acute effects of delta-9-tetrahydrocannabinol on dopaminergic activity in several rat brain areas, Pharmacol. Biochem. Behav. 42 (1992) 269-275.
86. J.L. Martin-Calderon, R.M. Munoz, M.A. Villanua, et al., Characterization of the acute endocrine actions of (-)-11-hydroxy-delta8- tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats, Eur. J. Pharmacol. 344 (1998) 77-86.
87. J.J. Fernandez-Ruiz, R.M. Munoz, J. Romero, M.A. Villanua, A. Makriyannis, J.A. Ramos, Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics, Biochem. Pharmacol. 53 (1997) 1919-1927.
88. C.G. Smith, C.E. Moore, N.F. Besch, P.K. Besch, The effect of marihuana (delta-9-tetrahydrocannabinol) on the secretion of sex hormones in the mature male rhesus monkey, Clin. Chem. 22 (1976) 1184.
89. A. List, B. Nazar, S. Nyquist, J. Harclerode, The effects of delta9-tetrahydrocannabinol and cannabidiol on the metabolism of gonadal steroids in the rat, Drug Metab. Dispos. 5 (1977) 268-272.
90. J. Harclerode, S.E. Nyquist, B. Nazar, D. Lowe, Effects of cannabis on sex hormones and testicular enzymes of the rodent, Adv. Biosci. 22-23 (1978) 395-405.
91. A. Jakubovic, E.G. McGeer, P.L. McGeer, Effects of cannabinoids on testosterone and protein synthesis in rat testis Leydig cells in vitro, Mol. Cell Endocrinol. 15 (1979) 41-50.
92. S. Husain, M. Lame, B. DeBoer, Rat testicular tissue glucose metabolism in the presence of delta-9-tetrahydrocannabinol, Proc. West Pharmacol. Soc. 22 (1979) 355-358.
93. A. Merari, A. Barak, M. Plaves, Effects of 1(2)-tetrahydrocannabinol on copulation in the male rat, Psychopharmacologia 28 (1973) 243-246.
94. M.E. Corcoran, Z. Amit, C.W. Malsbury, S. Daykin, Reduction in copulatory behavior of male rats following hashish injections, Res. Commun. Chem. Pathol. Pharmacol. 7 (1974) 779-782.
95. H. Schuel, M.C. Chang, D. Berkery, R. Schuel, A.M. Zimmerman, S. Zimmerman, Cannabinoids inhibit fertilization in sea urchins by reducing the fertilizing capacity of sperm, Pharmacol. Biochem. Behav. 40 (1991) 609-615.
96. A.M. Zimmerman, S. Zimmerman, A.Y. Raj, Effects of cannabinoids on spermatogenesis in mice, Adv. Biosci. 22-23 (1978) 407-418.
97. M.C. Chang, D. Berkery, R. Schuel, et al., Evidence for a cannabinoid receptor in sea urchin sperm and its role in blockade of the acrosome reaction, Mol. Reprod. Dev. 36 (1993) 507-516.
98. S.K. Das, B.C. Paria, I. Chakraborty, S.K. Dey, Cannabinoid ligand-receptor signaling in the mouse uterus, Proc. Natl. Acad. Sci. USA 92 (1995) 4332-4336.
99. B.C. Paria, S.K. Das, S.K. Dey, The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling, Proc. Natl. Acad. Sci. USA 92 (1995) 9460-9464.
100. S. Gonzalez, T. Bisogno, T. Wenger, et al., Sex steroid influence on cannabinoid CB(1) receptor mRNA and endocannabinoid levels in the anterior pituitary gland, Biochem. Biophys. Res. Commun. 270 (2000) 260-266.
101. B.C. Paria, H. Song, X. Wang, et al., Dysregulated cannabinoid signaling disrupts uterine receptivity for embryo implantation, J. Biol. Chem. 276 (2001) 20523-20528.
102. B.C. Paria, X. Zhao, J. Wang, S.K. Das, S.K. Dey, Fatty-acid amide hydrolase is expressed in the mouse uterus and embryo during the periimplantation period, Biol. Reprod. 60 (1999) 1151-1157.
103. M. Maccarrone, M. De Felici, M. Bari, F. Klinger, G. Siracusa, A. Finazzi-Agro, Down-regulation of anandamide hydrolase in mouse uterus by sex hormones, Eur. J. Biochem. 267 (2000) 2991-2997.
104. M. Dennedy, A. Friel, D. Houlihan, T. Smith, J. Morrison, Cannabinoids and the human uterus during pregnancy, J. Soc. Gynecol. Investig. 9 (Suppl.) (2002) 736.
105. A. Giuffrida, D. Piomelli, L. Burkman, et al., N-acylethanolamines in human reproductive fluids, 2001 Symposium on the Cannabinoids, International Cannabinoid Research Society, Burlington, Vermont, 2001, p. 106.
106. P.C. Schmid, B.C. Paria, R.J. Krebsbach, H.H. Schmid, S.K. Dey, Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation, Proc. Natl. Acad. Sci. USA 94 (1997) 4188-4192.
107. B.C. Paria, S.K. Dey, Ligand-receptor signaling with endocannabinoids in preimplantation embryo development and implantation, Chem. Phys. Lipids 108 (2000) 211-220.
108. B.C. Paria, D.D. Deutsch, S.K. Dey, The uterus is a potential site for anandamide synthesis and hydrolysis: differential profiles of anandamide synthase and hydrolase activities in the mouse uterus during the periimplantation period, Mol. Reprod. Dev. 45 (1996) 183-192.
109. J. Wang, B.C. Paria, S.K. Dey, D.R. Armant, Stage-specific excitation of cannabinoid receptor exhibits differential effects on mouse embryonic development, Biol. Reprod. 60 (1999) 839-844.
110. W.M. Liu, E.K. Duan, Y.J. Cao, Effects of anandamide on embryo implantation in the mouse, Life Sci. 71 (2002) 1623-1632.
111. B.C. Paria, W. Ma, D.M. Andrenyak, et al., Effects of cannabinoids on preimplantation mouse embryo development and implantation are mediated by brain-type cannabinoid receptors, Biol. Reprod. 58 (1998) 1490-1495.
112. L.Y. Yang, A. Kuksis, J.J. Myher, G. Steiner, Contribution of de novo fatty acid synthesis to very low density lipoprotein triacylglycerols: evidence from mass isotopomer distribution analysis of fatty acids synthesized from [2H6]ethanol, J. Lipid Res. 37 (1996) 262-274.
113. Z.M. Yang, B.C. Paria, S.K. Dey, Activation of brain-type cannabinoid receptors interferes with preimplantation mouse embryo development, Biol. Reprod. 55 (1996) 756-761.
114. T. Wenger, G. Fragkakis, P. Giannikou, K. Probonas, N. Yiannikakis, Effects of anandamide on gestation in pregnant rats, Life Sci. 60 (1997) 2361-2371.
115. T. Wenger, G. Fragkakis, P. Giannikou, N. Yiannikakis, The effects of prenatally administered endogenous cannabinoid on rat offspring, Pharmacol. Biochem. Behav. 58 (1997) 537-544.
116. T. Wenger, B.E. Toth, C. Juaneda, J. Leonardelli, G. Tramu, The effects of cannabinoids on the regulation of reproduction, Life Sci. 65 (1999) 695-701.
117. T. Wenger, J.J. Fernandez-Ruiz, J.A. Ramos, Immunocytochemical demonstration of CB1 cannabinoid receptors in the anterior lobe of the pituitary gland, J. Neuroendocrinol. 11 (1999) 873-878.
118. S. Gonzalez, J. Manzanares, F. Berrendero, et al., Identification of endocannabinoids and cannabinoid CB(1) receptor mRNA in the pituitary gland, Neuroendocrinology 70 (1999) 137-145.
119. T. Wenger, I. Gerendai, F. Fezza, et al., The hypothalamic levels of the endocannabinoid, anandamide, peak immediately before the onset of puberty in female rats, Life Sci. 70 (2002) 1407-1414.
120. M. Maccarrone, H. Valensise, M. Bari, N. Lazzarin, C. Romanini, A. Finazzi-Agro, Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage, Lancet 355 (2000) 1326-1329.
121. M. Maccarrone, H. Valensise, M. Bari, N. Lazzarin, C. Romanini, A. Finazzi-Agro, Progesterone up-regulates anandamide hydrolase in human lymphocytes: role of cytokines and implications for fertility, J. Immunol. 166 (2001) 7183-7189.
122. P. Piccinni, L. Rossaro, A. Graziotto, et al., Human natriuretic factor in cirrhotic patients undergoing orthotopic liver transplantation, Transplant. Int. 8 (1995) 51-54.
123. M.P. Piccinni, S. Romagnani, Regulation of fetal allograft survival by a hormone-controlled Th1- and Th2-type cytokines, Immunol. Res. 15 (1996) 141-150.
124. M.P. Piccinni, L. Beloni, C. Livi, E. Maggi, G. Scarselli, S. Romagnani, Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions, Nat. Med. 4 (1998) 1020-1024.
125. M. Maccarrone, T. Bisogno, H. Valensise, et al., Low fatty acid amide hydrolase and high anandamide levels are associated with failure to achieve an ongoing pregnancy after IVF and embryo transfer, Mol. Hum. Reprod. 8 (2002) 188-195.
126. S. Yura, Y. Ogawa, N. Sagawa, et al., Accelerated puberty and late-onset hypothalamic hypogonadism in female transgenic skinny mice overexpressing leptin, J. Clin. Invest. 105 (2000) 749-755.
127. V. Di Marzo, S.K. Goparaju, L. Wang, et al., Leptin-regulated endocannabinoids are involved in maintaining food intake, Nature 410 (2001) 822-825.
128. B. Park, H.M. Gibbons, M.D. Mitchell, M. Glass, Identification of the CB1 Cannabinoid Receptor and Fatty Acid Amide Hydrolase (FAAH) in the human Placenta, Placenta 24 (2003) 990-995.